Brief: IRLAB Granted End-Of-Phase 2 Meeting With FDA For Mesdopetam Program

IRLAB Therapeutics AB

03/01/2024 06:26

Jan 3 (Reuters) - IRLAB Therapeutics AB  IRLABa.ST :
    * IRLAB IS GRANTED AN END-OF-PHASE 2 MEETING WITH THE FDA
FOR THE
PHASE III-READY MESDOPETAM PROGRAM

Source text for Eikon:  ID:nMFN3wsDgm 
Further company coverage:  IRLABa.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))